FORUM REVIEW ARTICLE

Regenerative Medicine for the Heart: Perspectives on Stem-Cell Therapy

Gun-Sik Cho, Laviel Fernandez, and Chulan Kwon

Abstract

Significance: Despite decades of progress in cardiovascular biology and medicine, heart disease remains the leading cause of death, and there is no cure for the failing heart. Since heart failure is mostly caused by loss or dysfunction of cardiomyocytes (CMs), replacing dead or damaged CMs with new CMs might be an ideal way to reverse the disease. However, the adult heart is composed mainly of terminally differentiated CMs that have no significant self-regeneration capacity. **Recent Advances:** Stem cells have tremendous regenerative potential and, thus, current cardiac regenerative research has focused on developing stem cell sources to repair damaged myocardium. **Critical Issues:** In this review, we examine the potential sources of cells that could be used for heart therapies, including embryonic stem cells and induced pluripotent stem cells, as well as alternative methods for activating the endogenous regenerative mechanisms of the heart *via* transdifferentiation and cell reprogramming. We also discuss the current state of knowledge of cell purification, delivery, and retention. **Future Directions:** Efforts are underway to improve the current stem cell strategies and methodologies, which will accelerate the development of innovative stem-cell therapies for heart regeneration. *Antioxid. Redox Signal.* 21, 2018–2031.

Introduction

CORONARY (ISCHEMIC) HEART DISEASE—considered a progressive, incurable disorder—remains a major cause of global mortality and morbidity (84). The death and disability are, in part, attributed to the heart's limited regenerative capacity, as myocardial ischemia causes irreversible loss of cardiomyocytes (CMs) that can lead to heart failure. While heart transplantation may be an option to treat heart failure after unsuccessful medications and treatments, donor hearts are in short supply and transplantation rejection continues to be the most fearful obstacle to the success of transplantation. Thus, current cardiac regenerative studies are focusing on restoring the function of damaged heart by stimulating/manipulating endogenous heart cells or delivering exogenous cells.

Pluripotent stem cells (PSCs) from early embryos (called embryonic stem cells [ESCs]) (82) are capable of becoming all types of body cells under specific conditions both *in vivo* and *in vitro*. Thus, they hold great therapeutic potential for repairing nonregenerative organs, including the heart. How-

ever, establishing ESCs involves destroying early embryos (blastocysts), and this has continued to raise ethical problems. Furthermore, ESCs can form teratomas and are subject to immune rejection (99). The work of Yamanaka and colleagues in 2006 provided a partial solution to these problems by generating induced PSCs (iPSCs) from adult somatic cells (127). Since iPSCs can be generated from a patient's own somatic cells such as skin or blood cells, they circumvent ethical and patient-specificity problems associated with ESCs and, thus, constitute an attractive source of cells for therapeutic use. Research has also been directed toward the use of cardiac stem cells (CSCs) and cardiac progenitor cells (CPCs) and the development of a direct reprogramming method for the generation of CMs from somatic cells.

While the cell sources and methods described earlier have increased the hope for heart regeneration, there are critical hurdles to be overcome before putting them into practice. In this review, we will summarize currently available cell sources (Fig. 1) and methods for heart regeneration and discuss their potential and limitations.

FIG. 1. Potential cell sources for heart regeneration. Embryonic cell source: CMs and CPCs derived from ESCs or iPSCs. Adult cell source: CSCs, CFs, dedifferentiating or proliferating CMs. CMs, cardiomyocytes; CFs, cardiac fibroblasts; CPCs, cardiac progenitor cells; CSCs, cardiac stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

Embryonic Cell Source

ESC-derived CMs

ESCs can be considered an ideal source for replacing dysfunctional CMs, as their pluripotency and ability to self-renew allow them unlimited expansion and to differentiate into specialized cell types, such as CMs, under appropriate conditions. ESCs were first isolated from mouse blastocysts (82) and, subsequently, from other species, including rat (46), rabbit (36), monkey (131), and human (130). The pluripotency of ESCs is mediated *via* common transcription factors, including Oct3/4, Sox2, and Nanog (5, 14, 18, 95), but the maintenance of rodent and human ESCs (hESCs) depends on different signaling cascades [*i.e.*, leukemia inhibitory factor or fibroblast growth factor (FGF) signals for rodent or hESCs, respectively (1, 96)], suggesting different requirements for their self-renewal despite a common transcriptional network for pluripotency.

The cardiogenic potential of ESCs was well characterized by studies of mouse (26) and human (56) ESCs. Similar to adult CMs, hESC-derived CMs express the cardiac transcription factors GATA4 and Nkx2.5, as well as the cardiac-specific sarcomeric genes cardiac troponin I, cardiac troponin T (cTnT), atrial myosin light chain, ventricular myosin light chain (MLC-2v), and α -myosin heavy chain (α MHC) (56). Furthermore, the hESC-derived CMs express the CM gap junction proteins connexin (Cx)-43 and Cx45 and have action potentials similar to those of human ventricular myocytes (57). This suggests that ESC-derived CMs may be molecularly and functionally similar to CMs *in vivo*.

The transforming growth factor β , Wnt, FGF, and bone morphogenetic protein (BMP) signaling pathways play critical roles in establishing the cardiovascular system (30, 59, 66, 68, 83, 113, 114, 122, 139), and this knowledge has been applied for improving the efficiency of differentiating hESCs into CMs. The simplest way to obtain CMs from ESCs is to spontaneously differentiate ESCs by generating embryoid bodies (EBs), spherical cell aggregates formed *via* self-

aggregation of ESCs (56). However, the efficiency of generating CMs is very low with the EB method. In 2005, Mummery and colleagues developed a coculture method to increase the differentiation rate of hESCs, based on the *in vivo* observation that the anterior endoderm-like cell line, END-2, as feeders for hESCs, and, to some extent, this enhanced cardiac differentiation of hESCs (102). Later, direct coaggregation of ESCs and END-2 in suspension was found to greatly promote CM formation (136). The effect was mediated by fibronectin secreted from END-2 cells, affecting Wnt signaling in ESCs (21). Subsequently, Keller and colleagues demonstrated that temporally mimicking an early *in vivo* environment with a defined set of growth factors, including activin A, BMP4, FGFs, vascular endothelial growth factor (VEGF), and Dickkopf-1, is sufficient to change the fate of ESCs to precardiac mesoderm and can be used to generate CMs from ESCs with a high efficiency (51, 53). However, this method requires substantial optimization due to ESC line variations. Recent studies showed that sequential promotion and inhibition of Wnt signaling result in a high yield of CMs from hESCs in a robust manner (77), and that PSC-derived CMs can be expanded by small molecules (138).

To use ESC-derived CMs to improve heart function, it is necessary for them to interact properly with endogenous CMs and function normally after transplantation. Initial *in vivo* trials demonstrated that hESC-derived CMs are capable of forming new myocardium when transplanted into the hearts of rats (70) and pigs (57). The engrafted CMs expressed cardiac markers, including α MHC, MLC-2v, and atrial natriuretic factor (ANF), and the size of the CM graft significantly increased over time, implying their proliferation *in vivo*. Moreover, electrophysiological mapping and histopathological examination revealed that hESC-derived CMs could form pacemakers and couple electrically with surrounding host CMs in pig (70) and guinea pig (149) hearts. When these cells were transplanted into the infarcted heart in

rats, they appeared to improve the contractile function of the heart (69). The engrafted CMs were also electrically coupled to the host myocardium and improved the function of the postinfarcted heart (61, 89, 118). These studies suggest that hESC-derived CMs have characteristics similar to adult CMs and may be a suitable cell source to repair the damaged heart. However, despite the numerous advantages, there are several impediments to be overcome for therapeutic use. For instance, ESC-derived CMs show structural and functional properties of early-stage CMs instead of those of mature adult CMs (55) and remain immature after engraftment. In addition, there are safety concerns, such as tumor formation and immune rejection (99), and ethical issues on the isolation of ESCs from human blastocysts.

iPSC-derived CMs

In 2006, Yamanaka and colleagues developed a novel method to induce ESC-like cells—referred to as iPSC—from mouse fibroblasts by introducing a defined set of transcription factors (*i.e.*, Oct3/4, Sox2, and c-Myc) using viral vectors (127). Similar to ESCs, the iPSCs were capable of differentiating into derivatives of all three germ layers both *in vivo* and *in vitro* and of forming teratomas when transplanted into nude mice. The next year, human iPSCs (hiPSCs) were generated with the same combination of transcription factors (126) or a different set of factors (*i.e.*, Oct3/4, Sox2, Nanog, and Lin-28) (152). These factors were originally delivered *via* viral methods with retroviruses or lentiviruses, and, therefore, their random integration creates insertional mutations. Furthermore, incomplete silencing of *c-Myc*, a proto-oncogene, can lead to tumor formation (42). To resolve these issues, alternative methods have been developed with the LoxP/Cre system (119), Piggy Bac system (146), episomal plasmids (151), nonintegrating viruses (115), and siRNA (90). While the LoxP/Cre and Piggy Bac methods still leave small insertions, the others offer ways to generate integration-free iPSCs.

The differentiation potential of iPSCs into CMs has been extensively studied with iPSCs derived from mice (87), pigs (91), and humans (155). In comparison to hESCs, hiPSCs showed a lower efficiency of differentiation. However, both hiPSC- and hESC-derived CMs displayed similar patterns of cardiac gene expression, including *Nkx2.5*, *cTnT* (*troponin T type 2 [TNNT2]*), *αMHC*, *α-actinin*, *myosin light chain 2 atrial isoform*, *myosin light chain 2 ventricular isoform*, *ANF*, and *phospholamban* (155), with spontaneous rhythmic intracellular Ca^{2+} fluctuations (87). Moreover, iPSC-derived CMs contained atrial- and ventricular-like cells and responded to β -adrenergic signaling, a canonical CM signaling pathway (155). This suggests that iPSC-derived CMs are molecularly and functionally similar to ESC-derived CMs.

The clinical potential of iPSCs in cardiac repair was demonstrated in animal models. Okano and colleagues generated cardiac cell sheets with hiPSC-derived CMs in two-dimensional culture (86). These sheets showed spontaneous and synchronous beating, even after being detached from the culture dishes, and extracellular action potential propagation when two sheets were partially overlaid. hiPSC-derived cardiac cell patches can also be generated using a three-dimensional (3D) culture system (135). In this system, hiPSC-derived CMs were cultured in collagen type I to

generate contractile cardiac tissue patches, and their proliferation, hypertrophy, and alignment were controlled by mechanical stress. When these patches were transplanted into the adult rat heart, they formed grafts with contractile function (135). The hiPSC-derived CM sheets also improved cardiac function and left ventricular remodeling in porcine myocardial infarction (MI) models (54).

Given that iPSCs share numerous features in common with ESCs but circumvent the ethical and allogeneic transplantation problems associated with ESCs (126, 152), they are considered a suitable alternative to ESCs. However, genome-wide analysis of iPSCs and ESCs has revealed significant differences in gene expression, methylation, and microRNA (miRNAs) expression patterns (23, 145). The gene expression patterns of iPSCs also depended on their origins (33, 81). Moreover, Xu and colleagues showed that ESCs derived from a C57BL/6 mouse could induce teratoma formation without immune rejection, whereas some of the iPSCs derived from the same mouse resulted in T-cell-dependent immune rejection and failed to form teratomas. It turned out that the immunological difference between ESCs and iPSCs was caused by the abnormal expression of antigens in iPSCs (158). This indicates that iPSCs could have immunogenic problems, which may be linked to mutations that occur before, during, or after reprogramming (35). Thus, it will be necessary to evaluate genetic and epigenetic modifications and immunogenicity of iPSCs before clinical applications.

Cardiac progenitor cells

While the potential of CSCs remain to be further clarified, the biology of CPCs has been extensively studied both *in vivo* and *in vitro*. CPCs are identified in developing embryos and used as building blocks to generate the heart during embryogenesis (Fig. 2). The basic helix-loop-helix transcription factor mesoderm posterior 1 (*Mesp1*) is transiently expressed in the primitive streak during gastrulation and marks early CPCs (110, 111). *Mesp1*⁺ CPCs migrate anteriorly and form the first heart field (FHF) and second heart field (SHF) (17, 52, 92, 140). FHF cells give rise to the atria and left ventricle, whereas the outflow tract, right ventricle, and some of the atria are derived from the SHF. The heart fields express late CPC markers, such as *Islet1* (*Isl1*), fetal liver kinase 1 (*Flk1*), and *Nkx2.5*, which are often used to identify and isolate CPCs from ESCs/iPSCs (44, 52, 92, 147). Similar to CPCs found *in vivo*, ESC/iPSC-derived CPCs have the capability of expanding and differentiating into various types of cardiac cells, including CMs, smooth muscle cells, and endothelial cells *in vitro* (52, 64, 67, 92, 147). With this capability, CPCs are thought to have tremendous regenerative potential to repair damaged hearts. However, although they can be expanded by Wnt, Notch, and Fgf signals (25, 64, 65), CPCs are heterogeneous cells that spontaneously differentiate, and no method is available to clonally expand them in a renewal state. This poses a concern for potential PSC carryovers that can lead to tumor formation. A recent study showed that a subset of CPCs can undergo self-renewal as a homogeneous population in a dedicated cellular environment (117). Determining their environmental factors may enable long-term maintenance and mass production of CPCs. When engrafted into infarcted heart, ESC-derived CPCs differentiated into adult-sized CMs with Cx43 expression, reconstitute ~20%

FIG. 2. Cardiac development and markers. Cell surface markers are shown in gray. ICM, inner cell mass; A, anterior; FHF, first heart field (red), P, posterior; SHF, second heart field (blue). To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

of the scar tissue in a nonhuman primate model (12). Consistently, unlike PSC-derived CMs, PSC-derived CPCs appear to differentiate into mature CMs and vascular cells in the adult mouse heart without causing teratomas or arrhythmias (24, 98). While these studies revealed the unique potential of CPCs to form adult-like CMs for heart regeneration, further investigation will be required to determine their morphological and functional maturation, coupling, and functional integration with host myocardium, and long-term survival and effects on heart function.

Adult Cell Source

Cardiac stem cells

The adult heart is considered a terminally differentiated organ that lacks regenerative capacity. In fact, nearly all CMs withdraw from the cell cycle shortly after birth in mammals (79, 109). However, the human heart contains cycling myocytes under both normal and pathological conditions (9, 94, 106), and by measuring the concentration of ^{14}C in the DNA, Frisen and colleagues proposed that human CMs renew at the rate of 1% per year and 45% of the CMs are exchanged during an individual's life span (11). These studies suggested the existence of endogenous cells contributing to new myocytes in the adult heart. In fact, several groups have identified CSC populations in the adult heart, although their origins still remain unclear.

The tyrosine kinase receptor c-kit was originally identified as a marker of hematopoietic stem cells (48) and later shown to mark CSCs (3). Cardiac c-kit $^{+}$ cells were isolated from adult heart tissue and expressed cardiac transcription factors, such as Gata4, Gata5, MEF2C, and Nkx2.5. These cells were named CSCs, as they could self-renew and give rise to CMs, smooth muscle cells, and endothelial cells (8) after differentiation (7, 8). When injected into an ischemic heart, c-kit $^{+}$ CSCs differentiated into myocardium, vessels, and myocytes and reduced the infarct size with functional improvement (8), and c-kit $^{+}$ CSCs are necessary and sufficient for cardiac regeneration and repair (29). Stem cell antigen-1 (Sca-1), a cell-surface marker for somatic and hematopoietic stem cells,

was also shown to mark resident heart cells with stem cell properties (43, 85). Sca-1 $^{+}$ /CD31 $^{-}$ cells were identified in the adult myocardium as small interstitial cells and expressed cardiac transcription factors, such as Gata4 and MEF2C. Similar to c-kit $^{+}$ CSCs, transplantation of Sca-1 $^{+}$ /CD31 $^{-}$ cells after MI improved heart function by promoting angiogenesis and CM regeneration (144). Sca-1-deficient mice exacerbated cardiac hypertrophy with disorganized CMs and increased cell apoptosis under pressure overload, suggesting that Sca-1 may also have an essential role in cardiac remodeling and integrity (108). In addition to c-kit $^{+}$ or Sca-1 $^{+}$ CSCs, cells expressing ATP-binding cassette transporter ABCG2/breast cancer resistance protein 1 (BCRP) were identified as a CSC/CPC marker and shown to play a pivotal role in cardiac repair post-MI (40, 159). However, the existence and potential of CSCs remain controversial due to reproducibility issues (2, 153), and recent studies indicated that the benefits associated with adult stem cell injection might come from paracrine effects rather than from their myocardial differentiation (32). While cytokines and growth factors affecting angiogenesis and cell survival and proliferation, including VEGFs, BMPs, FGFs, and Wnt modulators, were proposed as the potential paracrine mediators responsible for cardiac protection and functional improvement (34, 75), further studies will be necessary to confirm their beneficial effects and mechanisms.

Cardiac fibroblasts

Although PSC-derived CMs/CPCs have demonstrated their therapeutic potential for cell-mediated heart regeneration, there are still concerns about carry-over undifferentiated PSCs that can form tumors. In addition, a large numbers of CMs/CPCs are required to replenish cells lost due to heart damage. Direct *in vivo* reprogramming may resolve these concerns, as the method enables generating CMs *in situ*, directly from endogenous non-CM cells. Ieda and colleagues developed the protocol for direct reprogramming of cardiac fibroblasts by introducing the transcription factors Gata4, Mef2c, and Tbx5 (GMT cocktail) in mice (47).

This method greatly reduced the steps required to produce CMs while limiting the formation of teratomas. Introducing these factors reprogrammed cardiac fibroblasts into CM-like cells (induced CMs [iCMs]) *in vitro* but they were morphologically and molecularly similar to neonatal CMs (47). However, intramyocardial delivery of the factors into infarcted hearts, whose fibroblasts were genetically labeled, resulted in conversion of cardiac fibroblasts into mature iCMs (105), suggesting that environmental factors, such as extracellular matrix (ECM), secreted factors, and contracting neighboring cells, may play an important role in their maturation. The GMT-treated mice showed significant improvement in heart function, particularly in cardiac output and stroke volume for approximately 3 months postintervention (105). Several other groups reported that the reprogramming efficiency can be enhanced by adding one more factor to the original GMT cocktail (120), fusing the MyoD transactivation domain to the transcription factors (41), or using miRNAs (miRNAs 1, 133, 208 and 499) instead of the cocktail (49).

With the abundance of cardiac fibroblasts and their *in situ* reprogramming, this method has great therapeutic potential to repair the damaged heart. Further investigation will be required to improve the reprogramming efficiency and to minimize the formation of incompletely reprogrammed or immature iCMs, as abnormal CMs can result in deleterious effects in patients, such as arrhythmias. In addition, it will be necessary to establish a robust protocol to generate iCMs in a highly reproducible manner (20). It is worth noting that given the low reprogramming efficiency, newly generated iCMs appear to be not sufficient to explain the high levels of functional improvement achieved by introducing the factors into the infarcted heart (120). Thus, it will be also of importance to investigate additional roles and mechanisms of the reprogramming factors leading to the functional improvement.

Existing CMs

While CMs in primitive animals, such as zebrafish, are capable of dedifferentiating and proliferating to repair damaged heart muscle (50), CMs in mammals are considered terminally differentiated and unable to re-enter the cell cycle. However, there is growing evidence that mammals retain the regenerative capacity at their neonatal stage (104) and the Hippo signaling pathway—known to control organ growth in *Drosophila* (101)—plays a key role in CM proliferation in the neonatal heart (141). Hippo inactivation, which leads to activation of its effector molecule Yes-associated protein 1 (Yap1), resulted in heart enlargement with increased CM proliferation during development (39). Similarly, genetic activation or deletion of Yap1 causes myocardial hyperplasia or hypoplasia, respectively, in the postnatal heart as well as in the prenatal heart, but CM size appeared to be unaffected (141). More recently, cardiac-specific deletion of Yap1 was shown to impair neonatal heart regeneration and increased levels of an active form of Yap1 in the adult heart promoted CM proliferation and dramatically enhanced heart regeneration after MI (148). These studies suggest that Hippo/Yap1 signaling is a crucial regulator of CM proliferation during embryonic and neonatal heart development and can push adult CMs to re-enter the cell cycle. However, it is unknown

whether CM proliferation in the adult heart requires dedifferentiation of CMs. Interestingly, increased levels of oncostatin M (OSM), an interleukin-6 (IL-6) class of cytokine, were shown to induce dedifferentiation of adult CMs, evidenced by loss of sarcomeric structures and upregulation of fetal genes and stem cell markers, and to enhance their cell-cycle progression (62). Thus, it appears that adult CMs are capable to undergo dedifferentiation and proliferation, and elucidating the precise mechanisms of the events may facilitate the development of an alternative way to regenerate the heart.

Cell Purification

For embryonic or adult cell-based heart regeneration, it is crucial to isolate specific precardiac or cardiac cell types without genetic manipulation and contamination, and efforts have been expended to identify cell-surface proteins (Fig. 2), which enables cell purification *via* antibody-mediated fluorescence-activated cell sorting (FACS).

PSC-derived CPCs can be isolated using cell-surface markers, such as KDR and/or PDGFRA (53, 150). Purified KDR/PDGFR⁺ cells express high levels of Mesp1 (21) and can differentiate into all types of cardiac cells, including CMs, endothelial cells, and smooth muscle cells (51, 53). FHF progenitors, which represent committed CPCs, can be isolated with the cell-surface protein hyperpolarization-activated, cyclic nucleotide-gated K⁺ 4 (HCN4) and FACS-purified HCN4⁺ cells preferentially differentiate into myocardial lineages (121). However, despite extensive *in vivo* characterization of the SHF, cell-surface molecules specifically expressed in SHF progenitors remain unclear. This may reflect the heterogeneity of SHF CPCs.

Signal-regulatory protein alpha (SIRPA) and vascular cell adhesion molecule 1 (VCAM-1) are cell-surface proteins highly expressed in PSC-derived CMs, and antibodies interacting with their extracellular domains can be used to isolate the CMs. FACS-purified SIRPA⁺ or VCAM-1⁺ cells were shown to contain 98% or 95%, respectively, of cTnT⁺ CMs derived from PSCs (28, 137). Different approaches were also proposed to purify PSC-derived CMs. Tetramethylrhodamine methyl ester perchlorate (TMRM) is a fluorescent dye that specifically labels mitochondria, and CMs can be distinguished from non-CMs by the intensity of TMRM (38). This method was shown to enrich PSC-derived CMs of approximately 99% purity (38). PSC-derived CMs can also be purified based on their metabolic properties to survive in a glucose-depleted and lactate-enriched condition (133). This method does not involve FACS, and therefore can be suitable for isolating a large quantity of CMs. While the described methods may enable us to efficiently purify CMs from PSC culture, CMs are heterogeneous, and it is unclear which chamber CMs are generated and isolated from PSCs. Determining the molecular and functional properties of CMs *in vivo* may enable us to identify and purify homogeneous or specific CMs from PSCs.

Most of the adult CSC/CPC markers, such as c-kit, Sca-1, and ABCG2/BCRP, are cell-surface proteins, and their antibodies are directly used for isolation (8, 85, 159). However, these proteins are also expressed in many other cell types, and the self-renewal and differentiation potential of the isolated cells remain to be confirmed.

FIG. 3. Cell delivery methods for heart regeneration. (A) Direct cardiac injection methods: intramyocardial and intracoronary injections. (B) Indirect cell delivery by homing mechanism. MCP, monocyte chemotactic protein; SDF-1, stromal-cell-derived factor 1. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

Unlike adult cell sources, CPCs/CMs isolated from PSC culture have concerns of tumorigenicity due to potential contamination of residual undifferentiated PSCs. A recent study suggested a way to selectively remove undifferentiated PSCs: They inhibited the activity of anti-apoptotic proteins (Bcl10 and survivin) enriched in PSCs with small-molecule inhibitors (*e.g.*, quercetin or YM155) (73). The inhibitors did not seem to affect the survival and function of differentiated cell types, such as dopamine neurons and smooth muscle cells (73). However, it will be necessary to determine whether the inhibitors do not affect cardiac differentiation and CM viability and function, because survivin deficiency causes premature cardiac death and CM proliferation defects (74).

Cell Delivery and Survival

To treat the damaged heart *via* cell transplantation, it is important to develop cell delivery strategies and protocols that enable precise and efficient introduction of cells into the site of injury. Direct and indirect methods are currently used for cell delivery (Fig. 3). Direct intramyocardial injection is a common way to deliver cells into the injured region of the heart (103). In this method, cells can be injected directly into infarcted or scar regions of ventricular wall. Although this method has the advantage of direct visualization and delivery with proven safety (103), needle punctures can cause mechanical leakage and lead to massive loss of cells injected (129). Intracoronary infusion is another option to deliver cells into the myocardial region of injury. While this approach can minimize cell leakage and may limit their systemic diffusion, injected cells may not be retained well (16) and can cause acute myocardial ischemia and myocardial microinfarction (143). Cells may be delivered *via* a homing system, which enables endogenous or exogenous cells to migrate to a specific region. Homing systems generally depend on chemoattractants expressed in injured tissues, and cell delivery is often done systemically. On MI, expression levels of chemoattractants, such as stromal-cell-derived factor 1 (SDF-1) (4), monocyte chemotactic protein (MCP)-1 (128), and MCP-3 (112), were shown to increase in the heart and this could lead to cell homing to the damaged tissue. In fact, increased levels

of SDF-1 and the SDF-1 receptor CXCR4 in mesenchymal stem cells (MSCs) enhanced the homing efficiency and improved cardiac function (4, 22, 154, 156). Similarly local overexpression of MCP-3 was shown to improve cardiac function by recruiting MSCs to the injured cardiac tissue (112). Homing systems can also be activated by growth factors, such as stem cell factor, VEGF, neural growth factor, granulocyte-colony stimulating factor, insulin-like growth factor, hepatocyte growth factor, and FGF [for review, see Taghavi and George (125)]. However, it is unknown whether a homing system can be used to deliver PSC-derived CPCs/CMs, and its clinical efficacy remains to be determined.

After cell delivery, the majority of injected cells are often washed out, and the engrafted cells do not survive long enough in the host heart. Thus, current cardiac tissue engineering focuses on developing methods to improve cell retention and survival of grafted cells (Fig. 4). Endogenous CMs are tightly attached to ECM molecules, such as laminin, collagen, fibronectin, and entactin, that typically provide structural support and play crucial roles in cell growth, wound healing, and fibrosis (71). For this reason, much effort has been put into the development of matrices that mimic native ECM. For instance, synthetic hydrogels share physical

FIG. 4. Cell survival and retention factors. SOD, superoxide dismutase. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

and biomechanical properties to native ECM and have widely been used as a 3D scaffold in tissue engineering (31). Intra-myocardial injection of hydrogel-encapsulated CSCs supplemented with ECM binding proteins significantly improved viability, proliferation, and long-term retention of the CPCs after MI (88). However, progressive loss of engrafted cells over time still needs to be resolved (88). Collagen is a natural ECM component and has been frequently used for tissue grafts, because it offers many advantages for cell transplantation such as low immunogenicity and biodegradability (13, 72). Coinjection with collagen matrices was shown to significantly enhance the survival rate of engrafted ESC-derived CMs and contribute to functional improvement of ischemic rat hearts (63). Similarly, the survival rate of hESC-derived CMs was significantly increased when they were delivered with matrigel (gelatinous ECM mixture from mouse sarcoma cells) into the infarcted heart of athymic rats (69). Addition of AVAD-fmk (antiapoptotic agent), cyclosporine A (immunosuppressant), pinacidil (ATP-dependent K^+ channel opener), and insulin-like growth factor 1 (described as prosurvival cocktail together with matrigel) further enhanced their survival (69).

Other prosurvival cocktail have been developed. miRs significantly improved CPC engraftment without ECM in a murine infarct model (45). The cocktail included miR-21, miR-24, and miR-221 that bind to the 3' UTR region of Bim, an apoptotic activator, and suppress its expression (45). These prosurvival cocktail studies suggest that cell death caused by apoptosis is an important factor affecting the cell engraftment. Apoptotic signaling in transplanted cells can also be inhibited by heat shock protein 70, whose expression is induced by heat shock (93) or by activation of the serine-threonine kinase Akt that targets the apoptotic molecules Bcl-2 and caspases (58). Heatshock treatment improved graft size of cardiac-enriched hESC progeny about threefold in rat hearts (70), and Akt overexpression reduced the percentage of engrafted neonatal CM undergoing apoptosis by 40% (157). While these studies point to the importance of blocking apoptotic pathways for cell survival in host myocardium, it remains to be determined whether the proposed methods have long-term effects.

While the approaches described earlier sought to develop cell-surviving methods through cell-autonomous mechanisms, it is also important to understand the cellular environment of damaged myocardium as it directly influences cell engraftment. For example, oxidative stress—caused by the imbalance between reactive oxygen species (ROS) levels and antioxidant defense—is increased in the failing heart (134) and can cause heart failure (97).

ROS are chemically reactive molecules, such as oxygen ions and peroxides, and are naturally generated by normal oxygen metabolism. Since high ROS levels increase oxidative stress, their levels are usually kept low by antioxidant molecules, such as vitamins C and E, superoxide dismutase (SOD), and glutathione peroxidase (132). Injured heart tissues are exposed to high ROS levels, and this condition adversely affects the survival and function of endogenous CMs (19, 142). Thus, high levels of ROS could negatively affect the viability of injected cells in the damaged heart. Indeed, SOD treatment increased the survival rate of engrafted skeletal myoblasts in the heart (124), and increasing antioxidant levels in the ischemic heart enhanced survival and

proliferation of CSCs engrafted to the myocardium (37). The beneficial effect was also observed when injected cells were pretreated with N-acetylcysteine that increases antioxidant levels (27). Since mitochondria are the major source of ROS (15), ROS levels might be more efficiently controlled by manipulating thioredoxin reductase-2, a key regulator of the overall emission of peroxides from cardiac mitochondria (123).

Although these studies demonstrated the importance of altering oxidative environment and the potential of antioxidants for survival of grafted cells, high-dose antioxidants were shown to negatively affect genetic stability, which may predispose to cancer (76). Similarly, increased levels of the angiogenic factors VEGF (107) and hypoxia inducible factor-1 α (6) could improve survival of grafted cells by enhancing blood vessel formation, and their overexpression is closely associated with tumor development (10, 116). Thus, it will be critical to determine safe dose ranges of antioxidants or angiogenic factors when they are used for cell transplantation therapies.

Outlook

Stem cells have enormous potential for treating heart failure. Efforts are now underway around the world to improve the current strategies and methodologies for heart regeneration, which may be applied for clinical interventions in the near future. As discussed, methods, including stem cell differentiation, purification, maturation, delivery, survival, and retention, should be thoroughly tested and optimized for stem cells to be used for clinical applications. New approaches may be needed to overcome obstacles, such as those that have been encountered in clinical trials.

In addition to cell-based therapies, the potential of stem cells is being actively investigated with multidisciplinary approaches. There are ongoing trials to generate bioartificial hearts *in vitro* by recellularizing a decellularized heart with CMs (100) or CPCs derived from PSCs (78). A novel *in vivo* method is under development for generating an entire organ by introducing donor iPSCs into host blastocysts of different species that are incapable of forming the organ (60). A therapeutic method could be sought from another direction such as 3D printers that have now been applied to generate organs using a special nozzle which can provide cells and a matrix of a specific shape (80). As such, integration of new technologies with stem cells is expected to facilitate and accelerate the development of innovative stem-cell therapies for heart regeneration, which may lead to cures for heart failure in the future.

Acknowledgments

The authors thank Kwon laboratory members for helpful discussions. This work was supported by grants from NHLBI/NIH (R01HL111198, R00HL092234), MSCRF, and the Magic That Matters Fund.

References

1. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, and Thomson JA. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. *Dev Biol* 227: 271–278, 2000.

2. Andersen DC, Andersen P, Schneider M, Jensen HB, and Sheikh SP. Murine “cardiospheres” are not a source of stem cells with cardiomyogenic potential. *Stem Cells* 27: 1571–1581, 2009.
3. Anversa P, Urbanek K, Rota M, Kajstura J, Leri A, and Bolli R. Cardiac stem cells in the failing human heart. *Microsc Microanal* 11: 904–905, 2005.
4. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, and Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. *Lancet* 362: 697–703, 2003.
5. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, and Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 17: 126–140, 2003.
6. Azarnoush K, Maurel A, Sebbah L, Carrion C, Bissery A, Mandet C, Pouly J, Bruneval P, Hagege AA, and Menasche P. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. *J Thorac Cardiovasc Surg* 130: 173–179, 2005.
7. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins RW, Lecapitaine N, Cascapera S, Beltrami AP, D'Alessandro DA, Zias E, Quaini F, Urbanek K, Michler RE, Bolli R, Kajstura J, Leri A, and Anversa P. Human cardiac stem cells. *Proc Natl Acad Sci U S A* 104: 14068–14073, 2007.
8. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, and Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 114: 763–776, 2003.
9. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, and Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med* 344: 1750–1757, 2001.
10. Bergers G and Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer* 8: 592–603, 2008.
11. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, and Frisen J. Evidence for cardiomyocyte renewal in humans. *Science* 324: 98–102, 2009.
12. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, Bellamy V, Rucker-Martin C, Barbry P, Bel A, Bruneval P, Cowan C, Pouly J, Mitalipov S, Gouadon E, Binder P, Hagege A, Desnos M, Renaud JF, Menasche P, and Puceat M. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. *J Clin Invest* 120: 1125–1139, 2010.
13. Boccafroschi F, Habermehl J, Vesentini S, and Mantovani D. Biological performances of collagen-based scaffolds for vascular tissue engineering. *Biomaterials* 26: 7410–7417, 2005.
14. Boiani M and Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. *Nat Rev Mol Cell Biol* 6: 872–884, 2005.
15. Boveris A, Oshino N, and Chance B. The cellular production of hydrogen peroxide. *Biochem J* 128: 617–630, 1972.
16. Bui QT, Gertz ZM, and Wilensky RL. Intracoronary delivery of bone-marrow-derived stem cells. *Stem Cell Res Ther* 1: 29, 2010.
17. Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J, and Evans S. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev Cell* 5: 877–889, 2003.
18. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, and Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* 113: 643–655, 2003.
19. Chandra M, Surendra K, Kapoor RK, Ghatak A, Kaur G, Pandey NR, and Misra MK. Oxidant stress mechanisms in heart failure. *Boll Chim Farm* 139: 149–152, 2000.
20. Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M, Gregoire S, Engels MC, Rajarajan K, Karra R, Abel ED, Wu JC, Milan D, and Wu SM. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. *Circ Res* 111: 50–55, 2012.
21. Cheng P, Andersen P, Hassel D, Kaynak BL, Limphong P, Juergensen L, Kwon C, and Srivastava D. Fibronectin mediates mesendodermal cell fate decisions. *Development* 140: 2587–2596, 2013.
22. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG, and Kong D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. *Mol Ther* 16: 571–579, 2008.
23. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, Ambartsumyan G, Aimiwu O, Richter L, Zhang J, Khvorostov I, Ott V, Grunstein M, Lavon N, Benvenisty N, Croce CM, Clark AT, Baxter T, Pyle AD, Teitell MA, Pelegri M, Plath K, and Lowry WE. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. *Cell Stem Cell* 5: 111–123, 2009.
24. Christoforou N, Oskouei BN, Estes P, Hill CM, Zimmet JM, Bian W, Bursac N, Leong KW, Hare JM, and Gearhart JD. Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. *PLoS One* 5: e11536, 2010.
25. Cohen ED, Wang Z, Lepore JJ, Lu MM, Taketo MM, Epstein DJ, and Morrissey EE. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. *J Clin Invest* 117: 1794–1804, 2007.
26. Doetschman TC, Eistetter H, Katz M, Schmidt W, and Kemler R. The *in vitro* development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. *J Embryol Exp Morphol* 87: 27–45, 1985.
27. Drowley L, Okada M, Beckman S, Vella J, Keller B, Tobita K, and Huard J. Cellular antioxidant levels influence muscle stem cell therapy. *Mol Ther* 18: 1865–1873, 2010.
28. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanti AG, Gramolini A, and Keller G. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. *Nat Biotechnol* 29: 1011–1018, 2011.
29. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, Henning BJ, Stirparo GG, Papait R, Scarfo M, Agosti V, Viglietto G, Condorelli G, Indolfi C, Ottolenghi S, Torella D, and Nadal-Ginard B. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. *Cell* 154: 827–842, 2013.
30. Gadue P, Huber TL, Paddison PJ, and Keller GM. Wnt and TGF-beta signaling are required for the induction of

- an *in vitro* model of primitive streak formation using embryonic stem cells. *Proc Natl Acad Sci U S A* 103: 16806–16811, 2006.
31. Geckil H, Xu F, Zhang X, Moon S, and Demirci U. Engineering hydrogels as extracellular matrix mimics. *Nanomedicine (Lond)* 5: 469–484, 2010.
 32. Gersh BJ, Simari RD, Behfar A, Terzic CM, and Terzic A. Cardiac cell repair therapy: a clinical perspective. *Mayo Clin Proc* 84: 876–892, 2009.
 33. Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, and Wu JC. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. *PLoS One* 5: e8975, 2010.
 34. Gneocchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, and Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. *FASEB J* 20: 661–669, 2006.
 35. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N, Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisua Belmonte JC, Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, and Zhang K. Somatic coding mutations in human induced pluripotent stem cells. *Nature* 471: 63–67, 2011.
 36. Graves KH and Moreadith RW. Derivation and characterization of putative pluripotential embryonic stem cells from preimplantation rabbit embryos. *Mol Reprod Dev* 36: 424–433, 1993.
 37. Gurusamy N, Ray D, Lekli I, and Das DK. Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium. *J Cell Mol Med* 14: 2235–2239, 2010.
 38. Hattori F, Chen H, Yamashita H, Tohyama S, Satoh YS, Yuasa S, Li W, Yamakawa H, Tanaka T, Onitsuka T, Shimoji K, Ohno Y, Egashira T, Kaneda R, Murata M, Hidaka K, Morisaki T, Sasaki E, Suzuki T, Sano M, Makino S, Oikawa S, and Fukuda K. Nongenetic method for purifying stem cell-derived cardiomyocytes. *Nat Methods* 7: 61–66, 2010.
 39. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, and Martin JF. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. *Science* 332: 458–461, 2011.
 40. Higashikuni Y, Sainz J, Nakamura K, Takaoka M, Enomoto S, Iwata H, Sahara M, Tanaka K, Koibuchi N, Ito S, Kusuhara H, Sugiyama Y, Hirata Y, Nagai R, and Sata M. The ATP-binding cassette transporter BCRP1/ABCG2 plays a pivotal role in cardiac repair after myocardial infarction via modulation of microvascular endothelial cell survival and function. *Arterioscler Thromb Vasc Biol* 30: 2128–2135, 2010.
 41. Hirai H, Katoku-Kikyo N, Keirstead SA, and Kikyo N. Accelerated direct reprogramming of fibroblasts into cardiomyocyte-like cells with the MyoD transactivation domain. *Cardiovasc Res* 100: 105–113, 2013.
 42. Hoffman B and Liebermann DA. The proto-oncogene c-myc and apoptosis. *Oncogene* 17: 3351–3357, 1998.
 43. Holmes C and Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. *Stem Cells* 25: 1339–1347, 2007.
 44. Hsiao EC, Yoshinaga Y, Nguyen TD, Musone SL, Kim JE, Swinton P, Espineda I, Manalac C, deJong PJ, and Conklin BR. Marking embryonic stem cells with a 2A self-cleaving peptide: a NKX2-5 emerald GFP BAC reporter. *PLoS One* 3: e2532, 2008.
 45. Hu S, Huang M, Nguyen PK, Gong Y, Li Z, Jia F, Lan F, Liu J, Nag D, Robbins RC, and Wu JC. Novel microRNA pro-survival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. *Circulation* 124: S27–S34, 2011.
 46. Iannaccone PM, Taborn GU, Garton RL, Caplice MD, and Brenin DR. Pluripotent embryonic stem cells from the rat are capable of producing chimeras. *Dev Biol* 163: 288–292, 1994.
 47. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell* 142: 375–86, 2010.
 48. Ikuta K and Weissman IL. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. *Proc Natl Acad Sci U S A* 89: 1502–1506, 1992.
 49. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mirotsoy M, and Dzau VJ. MicroRNA-mediated *in vitro* and *in vivo* direct reprogramming of cardiac fibroblasts to cardiomyocytes. *Circ Res* 110: 1465–1473, 2012.
 50. Jopling C, Sleep E, Raya M, Marti M, Raya A, and Izpisua Belmonte JC. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* 464: 606–609, 2010.
 51. Kattman SJ, Adler ED, and Keller GM. Specification of multipotential cardiovascular progenitor cells during embryonic stem cell differentiation and embryonic development. *Trends Cardiovasc Med* 17: 240–246, 2007.
 52. Kattman SJ, Huber TL, and Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. *Dev Cell* 11: 723–732, 2006.
 53. Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, Ellis J, and Keller G. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. *Cell Stem Cell* 8: 228–240, 2011.
 54. Kawamura M, Miyagawa S, Miki K, Saito A, Fukushima S, Higuchi T, Kawamura T, Kuratani T, Daimon T, Shimizu T, Okano T, and Sawa Y. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. *Circulation* 126: S29–S37, 2012.
 55. Kehat I and Gepstein L. Human embryonic stem cells for myocardial regeneration. *Heart Fail Rev* 8: 229–236, 2003.
 56. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, Binah O, Itskovitz-Eldor J, and Gepstein L. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. *J Clin Invest* 108: 407–414, 2001.
 57. Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J, and Gepstein L. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. *Nat Biotechnol* 22: 1282–1289, 2004.
 58. Kim AH, Khursigara G, Sun X, Franke TF, and Chao MV. Akt phosphorylates and negatively regulates apoptosis

- signal-regulating kinase 1. *Mol Cell Biol* 21: 893–901, 2001.
59. Klaus A, Saga Y, Taketo MM, Tzahor E, and Birchmeier W. Distinct roles of Wnt/beta-catenin and Bmp signaling during early cardiogenesis. *Proc Natl Acad Sci U S A* 104: 18531–18536, 2007.
 60. Kobayashi T, Yamaguchi T, Hamanaka S, Kato-Itoh M, Yamazaki Y, Ibata M, Sato H, Lee YS, Usui J, Knisely AS, Hirabayashi M, and Nakauchi H. Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. *Cell* 142: 787–799, 2010.
 61. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, Sasse P, Rubenchik O, Fries JW, Wenzel D, Geisen C, Xia Y, Lu Z, Duan Y, Kettenhofen R, Jovinge S, Bloch W, Bohlen H, Welz A, Hescheler J, Jacobsen SE, and Fleischmann BK. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. *J Exp Med* 203: 2315–2327, 2006.
 62. Kubin T, Poling J, Kostin S, Gajawada P, Hein S, Rees W, Wietelmann A, Tanaka M, Lorchner H, Schimanski S, Szibor M, Warnecke H, and Braun T. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. *Cell Stem Cell* 9: 420–432, 2011.
 63. Kutschka I, Chen IY, Kofidis T, Arai T, von Degenfeld G, Sheikh AY, Hendry SL, Pearl J, Hoyt G, Sista R, Yang PC, Blau HM, Gambhir SS, and Robbins RC. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. *Circulation* 114: I167–I173, 2006.
 64. Kwon C, Arnold J, Hsiao EC, Taketo MM, Conklin BR, and Srivastava D. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. *Proc Natl Acad Sci U S A* 104: 10894–10899, 2007.
 65. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, and Srivastava D. Notch post-translationally regulates beta-catenin protein in stem and progenitor cells. *Nat Cell Biol* 13: 1244–1251, 2011.
 66. Kwon C, Cordes KR, and Srivastava D. Wnt/beta-catenin signaling acts at multiple developmental stages to promote mammalian cardiogenesis. *Cell Cycle* 7: 3815–3818, 2008.
 67. Kwon C, Qian L, Cheng P, Nigam V, Arnold J, and Srivastava D. A regulatory pathway involving Notch1/beta-catenin/Isl1 determines cardiac progenitor cell fate. *Nat Cell Biol* 11: 951–957, 2009.
 68. Ladd AN, Yatskevych TA, and Antin PB. Regulation of avian cardiac myogenesis by activin/TGFbeta and bone morphogenetic proteins. *Dev Biol* 204: 407–419, 1998.
 69. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, and Murry CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nat Biotechnol* 25: 1015–1024, 2007.
 70. Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, and Murry CE. Formation of human myocardium in the rat heart from human embryonic stem cells. *Am J Pathol* 167: 663–671, 2005.
 71. Langer R and Tirrell DA. Designing materials for biology and medicine. *Nature* 428: 487–492, 2004.
 72. Lee CH, Singla A, and Lee Y. Biomedical applications of collagen. *Int J Pharm* 221: 1–22, 2001.
 73. Lee MO, Moon SH, Jeong HC, Yi JY, Lee TH, Shim SH, Rhee YH, Lee SH, Oh SJ, Lee MY, Han MJ, Cho YS, Chung HM, Kim KS, and Cha HJ. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. *Proc Natl Acad Sci U S A* 110: E3281–E3290, 2013.
 74. Levkau B, Schafers M, Wohlschlaeger J, von Wnuck Lipinski K, Keul P, Hermann S, Kawaguchi N, Kirchhof P, Fabritz L, Stypmann J, Stegger L, Flogel U, Schrader J, Fischer JW, Hsieh P, Ou YL, Mehrhof F, Tiemann K, Ghanem A, Matus M, Neumann J, Heusch G, Schmid KW, Conway EM, and Baba HA. Survivin determines cardiac function by controlling total cardiomyocyte number. *Circulation* 117: 1583–1593, 2008.
 75. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, Matsushita N, Blusztajn A, Terrovitis J, Kusuoka H, Marban L, and Marban E. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. *J Am Coll Cardiol* 59: 942–953, 2012.
 76. Li TS and Marban E. Physiological levels of reactive oxygen species are required to maintain genomic stability in stem cells. *Stem Cells* 28: 1178–1185, 2010.
 77. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, Raval KK, Zhang J, Kamp TJ, and Palecek SP. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc Natl Acad Sci U S A* 109: E1848–E1857, 2012.
 78. Lu TY, Lin B, Kim J, Sullivan M, Tobita K, Salama G, and Yang L. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. *Nat Commun* 4: 2307, 2013.
 79. MacLellan WR and Schneider MD. Genetic dissection of cardiac growth control pathways. *Annu Rev Physiol* 62: 289–319, 2000.
 80. Mannoor MS, Jiang Z, James T, Kong YL, Malatesta KA, Soboyejo WO, Verma N, Gracias DH, and McAlpine MC. 3D printed bionic ears. *Nano Lett* 13: 2634–2639, 2013.
 81. Marchetto MC, Yeo GW, Kainohana O, Marsala M, Gage FH, and Muotri AR. Transcriptional signature and memory retention of human-induced pluripotent stem cells. *PLoS One* 4: e7076, 2009.
 82. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A* 78: 7634–7638, 1981.
 83. Marvin MJ, Di Rocco G, Gardiner A, Bush SM, and Lassar AB. Inhibition of Wnt activity induces heart formation from posterior mesoderm. *Genes Dev* 15: 316–327, 2001.
 84. Mathers CD and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 3: e442, 2006.
 85. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, Sano M, Toko H, Akazawa H, Sato T, Nakaya H, Kasanuki H, and Komuro I. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. *J Biol Chem* 279: 11384–11391, 2004.
 86. Matsuura K, Wada M, Shimizu T, Haraguchi Y, Sato F, Sugiyama K, Konishi K, Shiba Y, Ichikawa H, Tachibana A, Ikeda U, Yamato M, Hagiwara N, and Okano T. Creation of human cardiac cell sheets using pluripotent

- stem cells. *Biochem Biophys Res Commun* 425: 321–327, 2012.
87. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, Nguemo F, Menke S, Hausteiner M, Hescheler J, Hasenfuss G, and Martin U. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. *Circulation* 118: 507–517, 2008.
 88. Mayfield AE, Tilokee EL, Latham N, McNeill B, Lam BK, Ruel M, Suuronen EJ, Courtman DW, Stewart DJ, and Davis DR. The effect of encapsulation of cardiac stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function. *Biomaterials* 35: 133–142, 2013.
 89. Min JY, Yang Y, Converso KL, Liu L, Huang Q, Morgan JP, and Xiao YF. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. *J Appl Physiol* 92: 288–296, 2002.
 90. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, and Mori M. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell* 8: 633–638, 2011.
 91. Montserrat N, Bahima EG, Batlle L, Hafner S, Rodrigues AM, Gonzalez F, and Izpisua Belmonte JC. Generation of pig iPS cells: a model for cell therapy. *J Cardiovasc Transl Res* 4: 121–130, 2011.
 92. Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, Qyang Y, Bu L, Sasaki M, Martin-Puig S, Sun Y, Evans SM, Laugwitz KL, and Chien KR. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell* 127: 1151–1165, 2006.
 93. Mosser DD, Caron AW, Bourget L, Denis-Larose C, and Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. *Mol Cell Biol* 17: 5317–5327, 1997.
 94. Nadal-Ginard B, Kajstura J, Leri A, and Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. *Circ Res* 92: 139–150, 2003.
 95. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, and Smith A. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* 95: 379–391, 1998.
 96. Niwa H, Burdon T, Chambers I, and Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. *Genes Dev* 12: 2048–2060, 1998.
 97. Nojiri H, Shimizu T, Funakoshi M, Yamaguchi O, Zhou H, Kawakami S, Ohta Y, Sami M, Tachibana T, Ishikawa H, Kurosawa H, Kahn RC, Otsu K, and Shirasawa T. Oxidative stress causes heart failure with impaired mitochondrial respiration. *J Biol Chem* 281: 33789–33801, 2006.
 98. Nsair A, Schenke-Layland K, Van Handel B, Evseenko D, Kahn M, Zhao P, Mendelis J, Heydarkhan S, Awaji O, Vottler M, Geist S, Chyu J, Gago-Lopez N, Crooks GM, Plath K, Goldhaber J, Mikkola HK, and MacLellan WR. Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells. *PLoS One* 7: e45603, 2012.
 99. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, Muskheli V, Pabon L, Reinecke H, and Murry CE. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. *FASEB J* 21: 1345–1357, 2007.
 100. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, and Taylor DA. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. *Nat Med* 14: 213–221, 2008.
 101. Pan D. Hippo signaling in organ size control. *Genes Dev* 21: 886–897, 2007.
 102. Passier R, Oostwaard DW, Snapper J, Kloots J, Hassink RJ, Kuijk E, Roelen B, de la Riviere AB, and Mummery C. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. *Stem Cells* 23: 772–780, 2005.
 103. Perin EC and Silva GV. Stem cell therapy for cardiovascular disease. In: *Cardiovascular Genetics and Genomics for the Cardiologist*, edited by Dzau VJ and Liew C-C. Malden, MA: Blackwell Futura, 2007, pp. 225–245.
 104. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, and Sadek HA. Transient regenerative potential of the neonatal mouse heart. *Science* 331: 1078–1080, 2011.
 105. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu JD, and Srivastava D. *In vivo* reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. *Nature* 485: 593–598, 2012.
 106. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B, Kajstura J, Leri A, and Anversa P. Chimerism of the transplanted heart. *N Engl J Med* 346: 5–15, 2002.
 107. Retuerto MA, Schalch P, Patejunas G, Carbray J, Liu N, Esser K, Crystal RG, and Rosengart TK. Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. *J Thorac Cardiovasc Surg* 127: 1041–1049; discussion 1049–1051, 2004.
 108. Rosenblatt-Velin N, Ogay S, Felley A, Stanford WL, and Pedrazzini T. Cardiac dysfunction and impaired compensatory response to pressure overload in mice deficient in stem cell antigen-1. *FASEB J* 26: 229–239, 2012.
 109. Rubart M and Field LJ. Cardiac regeneration: repopulating the heart. *Annu Rev Physiol* 68: 29–49, 2006.
 110. Saga Y, Hata N, Kobayashi S, Magnuson T, Seldin MF, and Taketo MM. MesP1: a novel basic helix-loop-helix protein expressed in the nascent mesodermal cells during mouse gastrulation. *Development* 122: 2769–2778, 1996.
 111. Saga Y, Kitajima S, and Miyagawa-Tomita S. MesP1 expression is the earliest sign of cardiovascular development. *Trends Cardiovasc Med* 10: 345–352, 2000.
 112. Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z, McCarthy PM, and Penn MS. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. *Stem Cells* 25: 245–251, 2007.
 113. Schneider VA and Mercola M. Wnt antagonism initiates cardiogenesis in *Xenopus laevis*. *Genes Dev* 15: 304–315, 2001.
 114. Schultheiss TM, Burch JB, and Lassar AB. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. *Genes Dev* 11: 451–462, 1997.
 115. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, Nakata H, Tohyama S, Hashimoto H, Kodaira M, Okada Y, Seimiya H, Fusaki N, Hasegawa M, and Fukuda K. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. *Cell Stem Cell* 7: 11–14, 2010.

116. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. *Intern Med* 41: 79–83, 2002.
117. Shenje LT, Andersen P, Uosaki H, Fernandez L, Rainer PP, Cho GS, Lee DI, Zhong W, Harvey RP, Kass DA, and Kwon C. Precardiac deletion of Numb and Numblike reveals renewal of cardiac progenitors. *Elife* 3: e02164, 2014.
118. Singla DK, Hacker TA, Ma L, Douglas PS, Sullivan R, Lyons GE, and Kamp TJ. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. *J Mol Cell Cardiol* 40: 195–200, 2006.
119. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, and Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. *Cell* 136: 964–977, 2009.
120. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, Hill JA, Bassel-Duby R, and Olson EN. Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature* 485: 599–604, 2012.
121. Spater D, Abramczuk MK, Buac K, Zangi L, Stachel MW, Clarke J, Sahara M, Ludwig A, and Chien KR. A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells. *Nat Cell Biol* 15: 1098–1106, 2013.
122. Srivastava D and Kwon C. Signaling pathways involved in cardiogenesis. In: *Inter cellular Signaling in Development and Disease: Cell Signaling Collection*, edited by Dennis EA and Bradshaw RA. San Diego, CA: Academic Press, 2011, pp. 67–76.
123. Stanley BA, Sivakumaran V, Shi S, McDonald I, Lloyd D, Watson WH, Aon MA, and Paolocci N. Thioredoxin reductase-2 is essential for keeping low levels of H₂O₂ emission from isolated heart mitochondria. *J Biol Chem* 286: 33669–33677, 2011.
124. Suzuki K, Murtuza B, Beauchamp JR, Smolenski RT, Varela-Carver A, Fukushima S, Coppen SR, Partridge TA, and Yacoub MH. Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. *FASEB J* 18: 1153–1155, 2004.
125. Taghavi S and George JC. Homing of stem cells to ischemic myocardium. *Am J Transl Res* 5: 404–411, 2013.
126. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861–872, 2007.
127. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126: 663–676, 2006.
128. Tamura Y, Matsumura K, Sano M, Tabata H, Kimura K, Ieda M, Arai T, Ohno Y, Kanazawa H, Yuasa S, Kaneda R, Makino S, Nakajima K, Okano H, and Fukuda K. Neural crest-derived stem cells migrate and differentiate into cardiomyocytes after myocardial infarction. *Arterioscler Thromb Vasc Biol* 31: 582–589, 2011.
129. Teng CJ, Luo J, Chiu RC, and Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. *J Thorac Cardiovasc Surg* 132: 628–632, 2006.
130. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, and Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science* 282: 1145–1147, 1998.
131. Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Becker RA, and Hearn JP. Isolation of a primate embryonic stem cell line. *Proc Natl Acad Sci U S A* 92: 7844–7848, 1995.
132. Thomson MJ, Frenneaux MP, and Kaski JC. Antioxidant treatment for heart failure: friend or foe? *QJM* 102: 305–310, 2009.
133. Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, Hashimoto H, Suzuki T, Yamashita H, Satoh Y, Egashira T, Seki T, Muraoka N, Yamakawa H, Ohgino Y, Tanaka T, Yoichi M, Yuasa S, Murata M, Suematsu M, and Fukuda K. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. *Cell Stem Cell* 12: 127–137, 2013.
134. Tsutsui H, Kinugawa S, and Matsushima S. Oxidative stress and heart failure. *Am J Physiol Heart Circ Physiol* 301: H2181–H2190, 2011.
135. Tulloch NL, Muskheili V, Razumova MV, Korte FS, Regnier M, Hauch KD, Pabon L, Reinecke H, and Murry CE. Growth of engineered human myocardium with mechanical loading and vascular coculture. *Circ Res* 109: 47–59, 2011.
136. Uosaki H, Andersen P, Shenje LT, Fernandez L, Christiansen SL, and Kwon C. Direct contact with endoderm-like cells efficiently induces cardiac progenitors from mouse and human pluripotent stem cells. *PLoS One* 7: e46413, 2012.
137. Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, and Yamashita JK. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. *PLoS One* 6: e23657, 2011.
138. Uosaki H, Magadum A, Seo K, Fukushima H, Takeuchi A, Nakagawa Y, Moyes KW, Narazaki G, Kuwahara K, Laflamme M, Matsuoka S, Nakatsuji N, Nakao K, Kwon C, Kass DA, Engel FB, and Yamashita JK. Identification of chemicals inducing cardiomyocyte proliferation in developmental stage-specific manner with pluripotent stem cells. *Circ Cardiovasc Genet* 6: 624–633, 2013.
139. van Weerd JH, Koshiba-Takeuchi K, Kwon C, and Takeuchi JK. Epigenetic factors and cardiac development. *Cardiovasc Res* 91: 203–211, 2011.
140. Verzi MP, McCulley DJ, De Val S, Dodou E, and Black BL. The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. *Dev Biol* 287: 134–145, 2005.
141. von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, Ma Q, Ishiwata T, Zhou B, Camargo FD, and Pu WT. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. *Proc Natl Acad Sci USA* 109: 2394–2399, 2012.
142. von Harsdorf R, Li PF, and Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. *Circulation* 99: 2934–2941, 1999.
143. Vulliamt PR, Greeley M, Halloran SM, MacDonald KA, and Kittleson MD. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. *Lancet* 363: 783–784, 2004.
144. Wang X, Hu Q, Nakamura Y, Lee J, Zhang G, From AH, and Zhang J. The role of the sca-1+/CD31- cardiac progenitor cell population in postinfarction left ventricular remodeling. *Stem Cells* 24: 1779–1788, 2006.
145. Wilson KD, Venkatasubrahmanyam S, Jia F, Sun N, Butte AJ, and Wu JC. MicroRNA profiling of human-induced pluripotent stem cells. *Stem Cells Dev* 18: 749–758, 2009.

146. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, and Nagy A. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 458: 766–770, 2009.
147. Wu SM, Fujiwara Y, Cibulsky SM, Clapham DE, Lien CL, Schultheiss TM, and Orkin SH. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. *Cell* 127: 1137–1150, 2006.
148. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, Richardson JA, Sadek HA, Bassel-Duby R, and Olson EN. Hippo pathway effector Yap promotes cardiac regeneration. *Proc Natl Acad Sci U S A* 110: 13839–13844, 2013.
149. Xue T, Cho HC, Akar FG, Tsang SY, Jones SP, Marban E, Tomaselli GF, and Li RA. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. *Circulation* 111: 11–20, 2005.
150. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, and Keller GM. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. *Nature* 453: 524–528, 2008.
151. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin, II, and Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324: 797–801, 2009.
152. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, and Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318: 1917–1920, 2007.
153. Zaruba MM, Soonpaa M, Reuter S, and Field LJ. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. *Circulation* 121: 1992–2000, 2010.
154. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, Xu M, Zhu Y, Ashraf M, and Wang Y. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. *J Mol Cell Cardiol* 44: 281–292, 2008.
155. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, and Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. *Circ Res* 104: e30–e41, 2009.
156. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, and Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. *FASEB J* 21: 3197–3207, 2007.
157. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, and Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. *J Mol Cell Cardiol* 33: 907–921, 2001.
158. Zhao T, Zhang ZN, Rong Z, and Xu Y. Immunogenicity of induced pluripotent stem cells. *Nature* 474: 212–215, 2011.
159. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, and Sorrentino BP. The ABC transporter

Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med* 7: 1028–1034, 2001.

Address correspondence to:

Dr. Chulan Kwon
Division of Cardiology
Department of Medicine
Institute for Cell Engineering
Johns Hopkins University
720 Rutland Ave., Ross 954B
Baltimore, MD 21205

E-mail: ckwon13@jhmi.edu

Date of first submission to ARS Central, August 1, 2014; date of acceptance, August 17, 2014.

Abbreviations Used

3D = three-dimensional
 α MHC = α -myosin heavy chain
 A = anterior
 ABCG2 = ATP-binding cassette transporter
 ANF = atrial natriuretic factor
 BCRP = breast cancer resistance protein 1
 BMP = bone morphogenetic protein
 CF = cardiac fibroblast
 CM = cardiomyocyte
 CPC = cardiac progenitor cell
 CSC = cardiac stem cell
 cTnT = cardiac troponin T
 Cx = connexin
 EB = embryoid body
 ECM = extracellular matrix
 END-2 = endoderm-like cell
 ESC = embryonic stem cell
 FACS = fluorescence-activated cell sorting
 FGF = fibroblast growth factor
 FHF = first heart field
 Flk1 = fetal liver kinase 1
 GMT = Gata4, Mef2c, Tbx5
 HCN4 = hyperpolarization-activated, cyclic nucleotide-gated K 4
 hESC = human embryonic stem cell
 hiPSC = human induced pluripotent stem cell
 iCM = induced cardiomyocyte
 ICM = inner cell mass
 IL-6 = interleukin-6
 iPSC = induced pluripotent stem cell
 Isl1 = Islet1
 MCP = monocyte chemotactic protein
 Mesp1 = mesoderm posterior 1
 MI = myocardial infarction
 miRNA = microRNA
 MLC-2v = ventricular myosin light chain
 MSCs = mesenchymal stem cells
 OSM = oncostatin M
 P = posterior
 PSC = pluripotent stem cell
 ROS = reactive oxygen species
 Sca-1 = stem cell antigen-1

Abbreviations Used (Cont.)

SDF-1 = stromal-cell-derived factor 1
SHF = second heart field
SIRPA = signal-regulatory protein alpha
SOD = superoxide dismutase

TMRM = tetramethylrhodamine methyl ester perchlorate
TNNT2 = troponin T type 2
VCAM-1 = vascular cell adhesion molecule 1
VEGF = vascular endothelial growth factor
Yap1 = Yes-associated protein 1